Cryoskin is a non-invasive, body contouring treatment from Paris that is used for slimming, cellulite reduction, and toning. Cryoskin Slimming uses the science of cryolipolysis (cell death) through the concentrated application of heat and cold to destroy fat cells. Cryoskin Toning helps improve micro-circulation and speed up metabolism, which results in higher collagen and elastin production. This helps reduce cellulite and improve fine lines and wrinkles. *
The Slimming technique begins with heat and then a sharp decrease in temperature to +/- 4 degrees celcius to cause fat cell death (cryolipolysis). These cells will be passed out through the lymphatic system. Clients may return to normal activity immediately after. For best results, no sugar or carbohydrates should be consumed 2 hours before and after the treatment. Must allow a minimum of 14 days between slimming sessions.
The Toning treatment works by cooling subcutaneous fat areas (fat directly underneath the skin) of the legs, arms, face, etc. which creates vasodilation or expansion of the blood vessels. This stimulates collagen production, breaking down the fibers that create dimpling, while firming and tightening the skin.
Non-surgical facelift! Results seen immediately after one session.
Dramatic results that last weeks! We can’t stop the aging process, but we can slow it down. Major collagen and elastin production help lift the face, and reduce the appearance of fine lines and wrinkles. No Cryo Facial treatments with in 30 days of receiving Botox or 90 days of fillers.
*These statements have not been evaluated by the FDA. This service is not intended to diagnose, treat, prevent or cure any disease. Not everyone is appropriate to receive Cryoskin services including those who are pregnant or breastfeeding, diabetic, allergic to cold, have severe Reynaud's Syndrome and/or kidney or liver disease or any other issue impacting the lymphatic system.
A complimentary consultation is offered to give an estimate of how many sessions you will need to reach your goal.